Publication: The potential of EZH2 expression to facilitate treatment choice in stage II colorectal adenocarcinoma
Authors
Zhu, Xiaoqun ; He, Lu ; Zheng, Zhong ; Wang, Ya ; Yang, Jun ; Zhang, Biao ; Wang, Chaoshan ; Li, Zhiwen
item.page.secondaryauthor
item.page.director
Publisher
Universidad de Murcia. Departamento de BiologĂa Celular e HistologĂa
publication.page.editor
publication.page.department
DOI
https://doi.org/10.14670/HH-18-732
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Background. The current selection criteria of
patients with stage II colorectal carcinoma (CRC)
suitable for adjuvant therapy are not satisfactory.
Enhancer of zeste homolog 2 (EZH2) has been
demonstrated to be over-expressed in CRC. However,
data regarding the role of EZH2 in CRC survival
remains controversial, and little is known about it in
stage II CRC. Thus, we conducted this study to
investigate the clinical significance of EZH2 expression
in stage II CRC.
Methods. Cases with stage II CRC resected between
2015 and 2018 were retrospectively reviewed. EZH2
expression was analyzed by immunohistochemistry
using tissue microarrays. The relationship between
EZH2 expression and clinicopathological variables was
analyzed. Survival curves were estimated by the KaplanMeier approach.
Results. We found high EZH2 expression in 134 of
221 analyzable stage II tumors (60.63%). No significant
associations were observed between EZH2 expression
and common clinicopathological factors. Survival
analyses showed that cases receiving surgery alone had
inferior overall survival (OS) than those receiving
surgery and chemotherapy (P=0.0075) in stage II CRC
with high EZH2 expression, however, metastasis-free
survival (MFS) was similar between these two
subgroups. Treatment choice had no impact on the
survival of stage II CRC with low EZH2 expression.
Conclusion. The OS of stage II CRC with high
EZH2 expression improved more strikingly with surgery
and adjuvant chemotherapy than with surgery alone,
which suggests the potential of EZH2 expression as a
biomarker to help identify a subgroup of early-stage
CRC benefiting from surgery and adjuvant chemotherapy. More large-scale studies are warranted to
corroborate this finding and to further evaluate the
predictive nature of EZH2.
publication.page.subject
Citation
item.page.embargo
Ir a EstadĂsticas
Este Ătem está sujeto a una licencia Creative Commons. CC BY 4.0